Literature DB >> 7962286

Growth hormone secretion in critical illness: effect of dopamine.

G Van den Berghe1, F de Zegher, P Lauwers, J D Veldhuis.   

Abstract

The catabolic state is a major contributor to the morbidity and mortality of critical illness. The underlying mechanism is poorly understood. We examined the endogenous secretion of an anabolic protein, GH, and studied the effect exerted on its secretion by dopamine, a catecholamine that is frequently administered for cardiovascular purposes in critical care. In a randomized controlled study of critically ill adult polytrauma patients (n = 11), we evaluated the effect of prolonged (83- to 296-h) dopamine infusion (5 micrograms/kg.min, iv) on the dynamics of GH secretion and on serum insulin-like growth factor-I, cortisol, and insulin concentrations. The effect of brief (15- to 21-h) dopamine administration was documented in an additional randomized controlled cross-over study involving nine patients. The GH profiles, obtained by blood sampling every 20 min for 9 h during 2 consecutive nights, were examined by deconvolution analysis. GH release was found to be exclusively pulsatile in all patients. Prolonged and brief dopamine infusions appeared to have similar effects. Twenty-four hours before initiation or after withdrawal of dopamine infusion, mean serum GH concentrations, mean secretion rate, amount of GH per secretory burst, and secretory burst amplitude were low, but, respectively, a median of 17% (P = 0.028), 36% (P = 0.046), 40% (P = 0.008), and 94% (P = 0.002) higher than those during dopamine infusion. After dopamine withdrawal, increased GH secretion was detectable within 3 h. Dopamine's effect on GH release was specific, as this agent had no discernable effect on the elevated serum cortisol and insulin concentrations or the low plasma insulin-like growth factor-I levels within 24 h. In conclusion, the present data suggest that pulsatile GH secretion is low during critical illness and that dopamine infusion further attenuates GH secretion through amplitude modulation, possibly as a result of a direct inhibitory action on the somatotropes. The latter iatrogenic effect might further aggravate the catabolic state of critical illness.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7962286     DOI: 10.1210/jcem.79.4.7962286

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

1.  Activity of GH/IGF-I axis in trauma and septic patients during artificial nutrition: different behavior patterns?

Authors:  G Pittoni; G Gallioi; M Zanello; L Gianotti; M F Boghen; S Colombo; F Broglio; C Santoro; G Davià; M G Papini; S Destefanis; F Minuto; C Miola; E Ghigo
Journal:  J Endocrinol Invest       Date:  2002-03       Impact factor: 4.256

2.  Low IGF-I levels are often uncoupled with elevated GH levels in catabolic conditions.

Authors:  L Gianotti; F Broglio; G Aimaretti; E Arvat; S Colombo; M Di Summa; G Gallioli; G Pittoni; E Sardo; M Stella; M Zanello; C Miola; E Ghigo
Journal:  J Endocrinol Invest       Date:  1998-02       Impact factor: 4.256

Review 3.  [Effects of dopamine on cellular and humoral immune responses in septic patients].

Authors:  G Beck; C Hanusch; P Brinkkoetter; N Rafat; J Schulte; K van Ackern; B Yard
Journal:  Anaesthesist       Date:  2005-10       Impact factor: 1.041

Review 4.  "Renal dose" dopamine in surgical patients: dogma or science?

Authors:  P W Perdue; J R Balser; P A Lipsett; M J Breslow
Journal:  Ann Surg       Date:  1998-04       Impact factor: 12.969

5.  Protein-sparing effect in skeletal muscle of growth hormone treatment in critically ill patients.

Authors:  L Gamrin; P Essén; E Hultman; M A McNurlan; P J Garlick; J Wernerman
Journal:  Ann Surg       Date:  2000-04       Impact factor: 12.969

6.  Acute gonadotroph and somatotroph hormonal suppression after traumatic brain injury.

Authors:  Justin Wagner; Joshua R Dusick; David L McArthur; Pejman Cohan; Christina Wang; Ronald Swerdloff; W John Boscardin; Daniel F Kelly
Journal:  J Neurotrauma       Date:  2010-06       Impact factor: 5.269

7.  Benchmarking clinical outcomes and the immunocatabolic phenotype of chronic critical illness after sepsis in surgical intensive care unit patients.

Authors:  Julie A Stortz; Juan C Mira; Steven L Raymond; Tyler J Loftus; Tezcan Ozrazgat-Baslanti; Zhongkai Wang; Gabriela L Ghita; Christiaan Leeuwenburgh; Mark S Segal; Azra Bihorac; Babette A Brumback; Alicia M Mohr; Philip A Efron; Lyle L Moldawer; Frederick A Moore; Scott C Brakenridge
Journal:  J Trauma Acute Care Surg       Date:  2018-02       Impact factor: 3.313

8.  The activity of GH/IGF-I axis in anorexia nervosa and in obesity: a comparison with normal subjects and patients with hypopituitarism or critical illness.

Authors:  L Gianotti; F Broglio; J Ramunni; F Lanfranco; C Gauna; A Benso; M Zanello; E Arvat; E Ghigo
Journal:  Eat Weight Disord       Date:  1998-06       Impact factor: 4.652

9.  Activity of GH/IGF-1 axis in burn patients: comparison with normal subjects and patients with GH deficiency.

Authors:  L Gianotti; M Stella; D Bollero; F Broglio; F Lanfranco; G Aimaretti; S Destefanis; M Casati; G Magliacani; E Ghigo
Journal:  J Endocrinol Invest       Date:  2002-02       Impact factor: 4.256

10.  Full neurological recovery after extreme hypoglycemia during intensive insulin therapy: a case report.

Authors:  Veerle M Piot; Anton Verrijcken; Marc Vanhoof; Ilse Mertens; Filiep Soetens
Journal:  J Diabetes Sci Technol       Date:  2012-07-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.